Clinical Trial Update: Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating nivolumab and ipilimumab, with or without the EXL01 live biotherapeutic product, for metastatic renal cell carcinoma; currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma
• Sarcomatoid Renal Cell Carcinoma

Drugs mentioned

• EXL01
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma | Phase 1 | Status: RECRUITING